Table 1.

Patient baseline and transplant characteristics

CharacteristicNGS cohort (n = 93)Overall (N = 110)
No.%IQRNo.%IQR
Median age at diagnosis (range), y56 (29-72)50-6155 (29-72)50-62
Median age at allo-HCT (range), y59 (42-72)53-6359 (38-72)53-64
Median interval from diagnosis to allo-HCT (range), mo14 (2-332)7-4815 (2-332)7-48
Recipient sex
 Male56606559
 Female37404541
Year of allo-HCT
 2004-201147515651
 2012-201746495449
Median donor age (range), y40 (19-75)30-5341 (19-75)30-53
Donor sex
 Male65707770
 Female28303330
Female donor to male recipient
 Yes16171816
 No77839284
ABO blood group compatibility
 ABO compatible53576155
 Minor mismatch15161816
 Major mismatch15162018
 Bidirectional10111110
Graft source
 Bone marrow3333
 Peripheral blood stem cells909710797
HLA match
 MRD42455146
 MUD 10/1039424440
 mMUD <10/1012131514
DIPSS classification at time of transplant evaluation
 Unknown891110
 Low5555
 Intermediate-131333633
 Intermediate-241445045
 High8987
DIPSS classification at allo-HCT
 Unknown1111
 Low1111
 Intermediate-120222523
 Intermediate-256606660
 High15161715
Donor/recipient CMV serostatus
 Donor–/recipient–8998
 Donor+/recipient–89109
 Donor–/recipient+36394036
 Donor+/recipient+40435045
 Unknown1111
Karnofsky performance status, %
 90-10037404642
 70-8032343734
 Unknown24262725
Median HCT comorbidity index (range)1 (0-7)0-31 (0-7)0-2
 032343835
 1-221232624
 >218192119
 Unknown22242523
GVHD prophylaxis
 Tacrolimus/sirolimus based849010091
 Tacrolimus based4444
 Cyclosporine/CellCept based5565
Type of MF
 Primary MF51555853
 Secondary polycythemia vera15161917
 Secondary essential thrombocythemia27293330
 Secondary MF42455247
Ruxolitinib use
 No66717871
 Yes27293229
Splenectomy before allo-HCT
 No81879485
 Yes12131615
Cytogenetics
 Unknown3344
 Favorable57616761
 Unfavorable20222422
 VHR13141514
MIPSS70+ v2.0 classification
 Unknown01715
 Intermediate risk11121110
 High risk47514743
 VHR35383532
  • CMV, cytomegalovirus; IQR, interquartile range.